Olfa Derbel
Overview
Explore the profile of Olfa Derbel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joly F, Bazan F, Garbay Decoopman D, Garbay D, Ouldbey Y, Follana P, et al.
JNCI Cancer Spectr
. 2024 Dec;
9(1).
PMID: 39673810
Background: Maintenance niraparib at an individualized starting dose (ISD) is established in platinum-sensitive recurrent ovarian cancer (PSROC). However, patients' perspectives on the burden of prolonged maintenance therapy have not been...
2.
Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J, et al.
Nat Commun
. 2024 Jul;
15(1):5932.
PMID: 39013886
PD-1/PD-L1 blockade has so far shown limited survival benefit for high-grade ovarian carcinomas. By using paired samples from the NeoPembrOv randomized phase II trial (NCT03275506), for which primary outcomes are...
3.
Ray-Coquard I, Savoye A, Schiffler C, Mouret-Reynier M, Derbel O, Kalbacher E, et al.
Nat Commun
. 2024 Jul;
15(1):5931.
PMID: 39013870
This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was unachievable assessed whether adding pembrolizumab (200 ...
4.
Mery B, Menetrier-Caux C, Montane L, Heudel P, Ray-Coquard I, Bachelot T, et al.
Breast Cancer (Dove Med Press)
. 2023 May;
15:311-325.
PMID: 37139242
Purpose: Metastatic endocrine-resistant breast cancer (MBC) is a disease with poor prognosis and few treatment options. Low lymphocyte count is associated with limited overall survival. In a prospective cohort of...
5.
Bidard F, Hardy-Bessard A, Dalenc F, Bachelot T, Pierga J, de La Motte Rouge T, et al.
Lancet Oncol
. 2022 Oct;
23(11):1367-1377.
PMID: 36183733
Background: In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show...
6.
Penault-Llorca F, Kwiatkowski F, Arnaud A, Levy C, Leheurteur M, Uwer L, et al.
Breast
. 2019 Dec;
49:132-140.
PMID: 31790959
Purpose: Genomic tests can identify ER-positive HER2-negative localized breast cancer patients who may not benefit from adjuvant chemotherapy. Such tests seem especially interesting in "intermediate" clinico-pathological risk categories. The psychological...
7.
Intidhar Labidi-Galy S, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, et al.
Gynecol Oncol
. 2019 Oct;
155(2):262-269.
PMID: 31604666
Objective: To investigate clinical factors associated with prolonged progression-free survival (PFS) and overall survival (OS) in relapsing epithelial ovarian cancer (EOC) patients with BRCA mutations and receiving olaparib as maintenance...
8.
Varnier R, Le Saux O, Chabaud S, Garin G, Sohier E, Wang Q, et al.
Eur J Cancer
. 2019 Jul;
118:156-165.
PMID: 31351267
Objectives: The objectives of this study were to identify actionable genomic alterations in the gynaecological subpopulation of the ProfiLER programme and to report clinical efficacy of recommended targeted treatment (RTT)....
9.
Intidhar Labidi-Galy S, Olivier T, Rodrigues M, Ferraioli D, Derbel O, Bodmer A, et al.
Clin Cancer Res
. 2017 Nov;
24(2):326-333.
PMID: 29084914
BRCA2 plays a central role in homologous recombination by loading RAD51 on DNA breaks. The objective of this study is to determine whether the location of mutations in the RAD51-binding...
10.
Derbel O, Heudel P, Cropet C, Meeus P, Vaz G, Biron P, et al.
PLoS One
. 2017 Feb;
12(2):e0158406.
PMID: 28158190
Purpose: The outcome of sarcoma has been suggested in retrospective and non-exhaustive studies to be better through management by a multidisciplinary team of experts and adherence to clinical practice guidelines...